Merck Enhances Aura Of Cancer Research With Vertex Aurora Kinase Inhibitor Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
VX-680 is ready to begin Phase I trials; aurora kinase inhibitor could have applicability in a number of cancer types. Merck will pay $20 mil. up front and as much as $350 mil. in milestones to Vertex.
You may also be interested in...
Merck Suspends Enrollment In Phase II Trial Of Vertex Leukemia Drug Due To Heart Signal
Trial that initiated in December aimed to enroll 270 adult patients, Merck tells “The Pink Sheet” DAILY. Those already enrolled may continue treatment pending a safety review.
Merck Suspends Enrollment In Phase II Trial Of Vertex Leukemia Drug Due To Heart Signal
Trial that initiated in December aimed to enroll 270 adult patients, Merck tells “The Pink Sheet” DAILY. Those already enrolled may continue treatment pending a safety review.
Merck Enters Macular Degeneration Field With Alnylam Deal
While Merck already markets glaucoma products (Timoptic, Trusopt, Cosopt), the company does not have an approved AMD therapy. Merck’s first AMD product is expected to reach the clinic in 2005 through an agreement with Alnylam; the companies will split profits of any marketed products in U.S.